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ABSTRACT
The advent of novel B-cell receptor pathway targeting agents like ibrutinib dramatically changed
management of B-cell malignancies. However, with concomitant anticoagulation (AC) and anti-
platelet (AP) therapy, ibrutinib is associated with increased bleeding. This post hoc analysis
aimed to determine the role of AC/AP therapy in patients with idelalisib-treated B-cell malignan-
cies and to establish if it contributes to increased bleeding events. Data from two idelalisib trials
(rituximab± idelalisib in chronic lymphocytic leukemia [CLL] and idelalisib monotherapy in indo-
lent non-Hodgkin lymphoma [iNHL]) were analyzed. Antithrombotic therapy was common
(36%–63%), with comparable bleeding incidence across treatment groups (14%–19%; p¼ 0.56).
Bleeding events of grade 3 occurred in 0.9% and 3.2% of the idelalisib-treated CLL and iNHL
cohorts, respectively. Our findings demonstrate no increase in bleeding events with simultan-
eous AC/AP treatment and idelalisib use. Hemorrhagic risk is prevalent in these patients and an
important consideration when evaluating available treatment options.
ClinicalTrials.gov identifiers: NCT01539512 and NCT01282424
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During the last decade, the treatment of B-cell malig-
nancies, mainly chronic lymphocytic leukemia (CLL)
and indolent non-Hodgkin lymphoma (iNHL), was rev-
olutionized with the clinical development of targeted
therapies. Several agents targeting the B-cell receptor
signaling pathway have been approved for first-line or
later-line use in the treatment of patients with CLL
and iNHL. Though these agents are highly efficacious
and well-tolerated, selecting the optimal therapeutic
strategy remains a challenge when dealing with a
patient whose comorbid condition may preclude the
use of a particular agent. The Bruton’s tyrosine kinase
inhibitor, ibrutinib, is routinely selected for manage-
ment of both CLL and iNHL. Compared to the registra-
tional trials, ibrutinib use in real-world studies has
been associated with an increased risk of bleeding (up
to a 20-fold increased risk of major bleeding) in
patients taking concomitant anticoagulation and anti-
platelet therapy [1], with a median time to ibrutinib
treatment discontinuation of 8months due to bleed-
ing events [2]. The UK ibrutinib real-world study of
315 patients reported that 44% of the patients had a
dose reduction, treatment interruption, or complete
cessation in the first 12months compared with the 4%
reported in the registration trial [3]. Although the
development of this agent addresses the unmet need
for effective therapy for the majority of patients with
CLL requiring treatment, long-term exposure may not
be an option for a select group of patients.
Both CLL and iNHL have a median age of onset of
65 years [4,5]. At diagnosis, up to 89% of these
patients have comorbidities [4,6], the most prevalent
being cardiovascular comorbidities [4,6–9]. Incidences
of hypertension, hyperlipidemia, coronary artery
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disease, and atrial fibrillation (AF) in elderly patients
with CLL are estimated to be 53%, 38%, 24%, and
20%, respectively [8]. Older, less-fit patients with CLL
or iNHL may have an increased thromboembolic risk
due to cardiovascular comorbidities [10] leading to
the use of antiplatelet and/or anticoagulant therapy
for thromboprophylaxis or management of thrombo-
embolism [11–13]. Serious hemorrhage may become a
concern in these patients given the following risk fac-
tors: baseline thrombocytopenia from bone marrow
infiltration, poor marrow reserve from the use of a
prior myelosuppressive regimen, and the possibility of
coexisting autoimmune cytopenias [14,15].
Idelalisib, a first-in-class, oral phosphatidylinositol 3-
kinase d (PI3Kd) inhibitor [16], selectively targets B
lymphocytes with minimal direct toxicity to other
hematopoietic cell types, including platelets [17,18].
Unlike targeting other PI3K isoforms, PI3Kd inhibition
does not affect platelet aggregation or signaling [17].
However, we wanted to understand if concomitant
antiplatelet and/or anticoagulant therapy use in
patients with a diagnosis of CLL or iNHL in idelalisib
registrational trials lead to higher rates of bleeding.
Therefore, a post hoc analysis of the two idelalisib
registrational trials was conducted to characterize the
use of concomitant anticoagulant and/or antiplatelet
therapy and bleeding events. Patients were treated
with idelalisib monotherapy or in combination with rit-
uximab in the setting of relapsed/refractory iNHL or
CLL, respectively, [19,20]. The use of anticoagulant
and/or antiplatelet agents or the presence of baseline
bleeding diathesis or severe thrombocytopenia were
not considered exclusions for participation in the trials.
Participants in these studies included patients with a
high comorbidity burden. The goals of this study were
to: (1) determine the degree of comorbidity burden
and the impact of idelalisib on bleeding events and
(2) describe the concomitant use of antithrombotic
therapy and bleeding incidence across treatment
groups, and characterize the timing and severity of
bleeding events in order to understand the potential
for hemorrhage after idelalisib exposure.
Methods
The analysis included data from 345 patients partici-
pating in the two registrational trials of idelalisib.
These studies were selected for analysis to permit con-
sistency with the approved indications of idelalisib for
CLL and follicular lymphoma (FL) and to minimize the
risk of adding confounders from earlier trials that
explored the use of idelalisib with different dosages or
with other combination strategies. Study 312-116
(NCT01539512) was a phase 3, randomized, double-
blind, placebo-controlled trial conducted at 90 sites in
the United States and Europe that enrolled patients
(N¼ 220) with relapsed/refractory CLL who were poor
candidates to receive cytotoxic agents [19]. Study 101-
09 (NCT01282424) was a phase 2 single-group, open-
label study conducted at 41 sites in the United States
and Europe (N¼ 125) [20]. Patients 18 years of age
with a confirmed diagnosis of iNHL (i.e. FL, small
lymphocytic lymphoma [SLL], lymphoplasmacytic
lymphoma with/without Waldenstr€om [WM], and mar-
ginal zone lymphoma [MZL]) treated with 2 prior
systemic therapies and refractory to both rituximab
and an alkylating agent, absolute neutrophil count
1.0 109/L, and platelet count 50 109/L were eli-
gible for the phase 2 study [20]. Additional details
regarding eligibility criteria are included in the
Supplementary Materials.
Patients with CLL were randomized to receive a
combination of idelalisib 150mg twice daily (BID) or
placebo plus 8 doses of rituximab; following unblind-
ing, patients in the placebo arm had the option to
receive idelalisib. In the iNHL trial, all patients received
idelalisib 150mg BID. All idelalisib-treated patients
received study drug until disease progression or
unacceptable toxicity, with the option for dose reduc-
tions to 100 or 75mg BID in the CLL trial [19,20].
Concomitant anticoagulant and/or antiplatelet therapy,
including warfarin use, was permitted in both trials.
Data cutoffs were 11 June 2014 (iNHL), and 15
October 2014 (CLL), which reflect the final data cuts
available for both registrational trials.
Anticoagulant/antiplatelet medications were identi-
fied using World Health Organization drug coding
(World Health Organization Anatomical Therapeutic
Chemical antithrombotic agents and drugs containing
acetylsalicylic acid). Comorbidities at randomization
were determined based on patient medical history
and coded using the Medical Dictionary for Regulatory
Activities version 17.0 (MedDRA 17.0). For the CLL
study, medical history terms were identified for comor-
bid conditions associated with increased bleeding risk.
All bleeding events occurring during the studies were
recorded and classified by investigators according to
MedDRA 17.0 preferred terms and graded using
Common Terminology Criteria for Adverse Events ver-
sion 4.0.3 (CLL study) and 3.0 (iNHL study). Adverse
events and concomitant medications were assessed
through 30 days after the last exposure.
For the CLL study, baseline characteristics were ana-
lyzed in the intent-to-treat population consisting of all
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randomized patients; all other analyses were per-
formed in patients who received 1 dose of study
medication. Comorbidity analyses were performed in
patient subgroups based on the presence/absence of
treatment-emergent bleeding events. Descriptive sta-
tistics are reported. Given the small sample sizes and
the post hoc nature of this analysis, no comparative
statistical analyses were performed.
Results
Patients
A total of 345 patients (CLL, n¼ 220; iNHL, n¼ 125)
were enrolled in the two trials. Median (range) dur-
ation of therapeutic exposure was 8.1 (0.3–19.5), 4.6
(0.1–14.6), and 6.6 (0.6–35.4) months in the idelali-
sibþ rituximab, placeboþ rituximab, and idelalisib
monotherapy groups, respectively. Demographics and
baseline disease characteristics in patients with CLL
and iNHL are presented in Supplemental Tables 1
and 2, respectively.
Baseline cytopenias were common in both studies
(Table 1). In the CLL study, baseline median  109/L
platelet (range) levels were 108 (3-284) for patients
receiving idelalisibþ rituximab and 104 (4-439) for
patients receiving placeboþ rituximab, and, in the
iNHL study, were 178 (15-535) for patients receiving
idelalisib monotherapy.
Comorbidities
In the CLL patients, the most common comorbidities
were hypertension (52%), chronic kidney disease
(34%), hyperlipidemia (34%), osteoarthritis (20%), and
diabetes (19%). In the iNHL patients, the most com-
mon were hypertension (35%), coronary artery disease
(5%), cardiac arrhythmia (4% not AF; 3% AF), and ven-
ous thromboembolism/pulmonary embolism (3%).
Analysis of comorbidities and their relationship to the
presence/absence of treatment-emergent bleeding
events showed no distinct pattern (data not shown)
across the three treatment groups.
Anticoagulant/antiplatelet therapy
Concomitant anticoagulant/antiplatelet use at any
time on study was frequent in all treatment groups
(idelalisibþ rituximab, 63%; placeboþ rituximab, 36%;
idelalisib monotherapy, 47%; Table 2). The most com-
monly used medications were aspirin, enoxaparin,
heparin/heparinoids, and warfarin. When aspirin was
excluded from the analysis, the use of anticoagulant/
antiplatelet therapy was reduced to 36%, 21%, and
34% in the idelalisibþ rituximab, placeboþ rituximab,
and idelalisib monotherapy groups, respectively.
Summary data reflecting duration of anticoagulant/
antiplatelet therapy were not available.
Bleeding events
In the idelalisibþ rituximab group, the median (range)
duration of follow-up for safety assessment was 8.9
(0.9–20.5) and 9.4 (2.9–17.4) months for patients with-
out or with treatment-emergent bleeding events,
respectively; in the placeboþ rituximab group, it was
5.6 (0.2–15.5) and 4.7 (0.4–13.2) months for patients
without or with bleeding events, respectively; and in
the idelalisib monotherapy group, it was 7.4 (1.5–35.4)
months for patients without and 11.8 (1.2–26.1)
months for patients with bleeding events.
Overall, proportions of patients experiencing bleed-
ing events (Figure 1(A)) were similar across the treat-
ment groups. The exposure-adjusted incidence of
bleeding events was 7.26/10,000 person-days (95%
confidence interval [CI], 4.43–11.21) in the idelali-
sibþ rituximab treatment group, 12.05/10,000 person-
days (95% CI, 7.46–18.42) in the placeboþ rituximab
group, and 4.49/10,000 person days (95% CI,
2.66–7.10) in the monotherapy group. The majority of
bleeding events occurred within the first 3months of
Table 1. Baseline hemogram data in the CLL and iNHL trials.
Baseline Cytopenia, n (%)
CLLa Idelalisib1 R (n5 110) CLLa PBO1 R (n5 108) iNHLb Idelalisib Monotherapy (n5 125)
Any Grade Grade 3 Any Grade Grade 3 Any Grade Grade 3
Anemia 83 (75.5) 7 (6.4) 79 (73.1) 12 (11.1) 64 (51.2) 1 (0.8)
Neutropenia 37 (33.6) 19 (17.3) 39 (36.1) 18 (16.7) 29 (23.2) 7 (5.6)
Thrombocytopeniac 68 (61.8) 18 (16.4) 66 (61.1) 30 (27.8) 43 (34.4) 3 (2.4)
CLL: chronic lymphocytic leukemia; iNHL: indolent non-Hodgkin lymphoma; PBO: placebo; R: rituximab.
aCLL inclusion criteria: severe neutropenia or thrombocytopenia caused by cumulative myelotoxicity from previous therapies (patients with any grade of
thrombocytopenia were allowed); data were analyzed in the safety analysis population.
biNHL inclusion criteria: absolute neutrophil count 1.0 x109/L and platelet count 50 x 109/L; data were analyzed in all patients who received
1 dose.
cGrade 3 thrombocytopenia ¼ <50 x 109/L; grade 1 thrombocytopenia ¼ <lower limit of normal.
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Idelalisibþ R (n¼ 110) PBOþ R (n¼ 108) Idelalisib Monotherapy (n¼ 125)
AC, AP, and/or thrombolytic 69 (62.7) 39 (36.1) 59 (47.2)
AC 38 (34.5) 22 (20.4) 41 (32.8)
Enoxaparin/enoxaparin sodium 17 (15.5) 7 (6.5) 22 (17.6)
Heparin/heparinoids 13 (11.8) 2 (1.9) 6 (4.8)
Warfarind 9 (8.2) 9 (8.3) 12 (9.6)
Tinzaparin 4 (3.6) 0 1 (0.8)
Dalteparin/dalteparin sodium 1 (0.9) 2 (1.9) 6 (4.8)
Dabigatran 1 (0.9) 1 (0.9) 0
Certoparin sodium 1 (0.9) 0 0
Fondaparinux 0 0 3 (2.4)
Nadroparin 0 1 (0.9) 2 (1.6)
Argatroban 0 0 1 (0.8)
Sulodexide 0 0 1 (0.8)
AP 44 (40.0) 23 (21.3) 32 (25.6)
Aspirin 44 (40.0) 22 (20.4) 30 (24.0)
Clopidogrel/clopidogrel bisulfate 5 (4.5) 1 (0.9) 1 (0.8)
Cilostazol 1 (0.9) 0 0
Prasugrel 0 1 (0.9) 0
Ticlopidine 0 0 1 (0.8)
Thrombolytic
Alteplasee 1 (0.9) 2 (1.9) 2 (1.6)
AC: anticoagulant; AP: antiplatelet; CLL: chronic lymphocytic leukemia; iNHL: indolent non-Hodgkin lymphoma; PBO: placebo; R: rituximab.
aPatients could be using >1 medication.
bSafety analysis population.
cAll patients who received 1 idelalisib dose.
dAll patients therapeutically anticoagulated.
en¼ 3, line clearing; n¼ 1, pulmonary embolism; n¼ 1, aortic aneurysm. One patient in the placeboþ R group received alteplase for venous catheter
occlusion for 1 day and later had 1 grade 3 and 1 grade 2 epistaxis event.
Figure 1. Incidence of bleeding events (A) overall and by grade 1/2 or 3 and (B) by 3-month increments after initiation of study
treatment. CLL: chronic lymphocytic leukemia; iNHL: indolent non-Hodgkin lymphoma. Percentage values based on original
patient sample size.
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study treatment (Figure 1(B)). Median (range) times to
onset of first bleeding event (any grade) were 37
(9–423), 29 (1–137), and 189 (7–519) days in the idela-
lisibþ rituximab, placeboþ rituximab, and idelalisib
monotherapy groups, respectively.
Of 59 patients with bleeding events, 40 (68%), 13
(22%), and 6 (10%) experienced highest grade 1, high-
est grade 2, and grade 3 events, respectively. No
intracranial or intraspinal hemorrhage was reported.
The distribution of patients by grade was similar for
the idelalisibþ rituximab and placeboþ rituximab
groups; most patients experienced grade 1 events
(idelalisibþ rituximab, 75%; placeboþ rituximab, 86%).
In patients receiving idelalisib monotherapy, the distri-
bution trended toward a more balanced profile across
grades. Most frequently reported grade 1 or 2 bleed-
ing events included epistaxis and contusion (Figure 2).
Across all treatment groups, only a single patient who
was receiving idelalisibþ rituximab as well as anti-
coagulant and antiplatelet therapy discontinued due
to a bleeding event of grade 4 hemoptysis (coughing
up blood).
Among patients receiving anticoagulant/antiplatelet
therapy, the incidence of bleeding events was similar
across treatment groups, irrespective of whether
aspirin was excluded or if anticoagulant/antiplatelet
use occurred within 30 days of the bleeding event
(Figure 3(A)). Among idelalisib-treated patients (idelali-
sibþ rituximab or idelalisib monotherapy), fewer
patients experienced bleeding events while receiving
antiplatelet therapy than while receiving anticoagulant
therapy (Figure 3(B)). As detailed in Figure 3(C), of the
30 patients receiving concomitant warfarin, seven
experienced bleeding events while on trial; all were
grade 1 with the exception of one case of grade 2
observed in the iNHL cohort.
When comparing the incidence of bleeding events
between groups which did or did not receive anti-
coagulant/antiplatelet treatment, the proportion of
patients experiencing bleeding events was similar
(18.8%–24.0%) across treatment arms and conditions,
with one exception: Lack of concomitant administra-
tion of anticoagulant/antiplatelet therapy correlated
with fewer bleeding events (idelalisibþ rituximab, with
vs without anticoagulant/antiplatelet treatment: 21.7%
vs 12.2%; idelalisib monotherapy: 24.0% vs 6.1%).
Twice as many patients who experienced treatment-
emergent bleeding events (n¼ 15/59 [25.4%]) as
patients who did not (n¼ 36/284 [12.7%]) had grade
3 thrombocytopenia at baseline. Platelet counts
remained stable or improved while on treatment with
idelalisib, and improvements tended to be more sub-
stantial in patients with baseline thrombocytopenia
below 100 K/lL compared with patients with platelet
counts above 100 K/lL (Supplemental Figure 1A
and 1B).
Severe (grade 3) bleeding events occurred in 1
patient (0.9%) treated with idelalisibþ rituximab (hem-
optysis), 1 (0.9%) treated with placeboþ rituximab
(epistaxis), and 4 (3.2%) treated with idelalisib mono-
therapy (melena, hematochezia, hematuria, and upper
gastrointestinal hemorrhage; each n¼ 1). The patient
treated with idelalisibþ rituximab who experienced
hemoptysis was receiving both anticoagulant and anti-
platelet therapy. The patient treated with place-
boþ rituximab had grade 4 thrombocytopenia both at
baseline and at the time of the event and received
1 day of anticoagulant therapy 7 days before the
bleeding event. Of the 4 patients receiving idelalisib
monotherapy that sustained a severe bleeding event,
2 were taking antiplatelet therapy and the other 2
Figure 2. Most frequent bleeding events by type and severity. CLL: chronic lymphocytic leukemia; iNHL: indolent non-Hodgkin
lymphoma; R: rituximab. Bleeding events reported in >1 patient shown.
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were not receiving any anticoagulant or antiplate-
let therapy.
Discussion
The development of highly effective therapies that tar-
get dysregulated pathways in CLL and iNHL has trans-
formed the treatment landscape with several novel
oral agents recently approved and adopted into
routine clinical practice [21,22]. Although highly effect-
ive and well-tolerated treatment options for relapsed
or refractory CLL and iNHL are available, certain risk
factors and comorbidities may preclude the use of
specific therapies. Longer follow-up on these novel
agents demonstrates new challenges including the
emergence of tolerability issues depending on the
patient’s comorbidities and the selected drug. BTK
inhibitor use carries the risk for increased bleeding
Figure 3. Incidence of bleeding events (A) in patients receiving anticoagulant and/or antiplatelet therapy, (B) while on anticoagu-
lant therapy alone or antiplatelet therapy alone, and (C) while on warfarin therapy. CLL: chronic lymphocytic leukemia; iNHL:
indolent non-Hodgkin lymphoma. Within 30 days of the event.
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events [1], which could lead to treatment discontinu-
ation. Our goal was to study and describe the rate of
bleeding for patients treated with idelalisib in the set-
ting of antiplatelet medications and/or anticoagulant
use and with baseline thrombocytopenia. These novel
agents can put the patients at risk for bleeding, and
the underlying malignancy can also predispose to
adverse effects that may require the initiation of anti-
platelet/anticoagulant therapy. Thus, there is the need
to carefully evaluate baseline bleeding risk, comorbid-
ities, and concurrent medications, particularly in
patients with hematologic malignancies who have a
prior medical history of a bleeding disorder or who
require the use of anticoagulant/antiplatelet agents.
To our knowledge, no prior data on bleeding events
has been reported for any drug targeting the PI3Kd
signaling pathway.
In this post hoc analysis of idelalisib registrational tri-
als, we evaluated whether idelalisib use impacts the
risk of bleeding events in patients at high risk for
bleeding (due to comorbidities or baseline thrombo-
cytopenia) and described the impact of the concomi-
tant use of antiplatelet and anticoagulant agents in
idelalisib-treated patients. The focus of this analysis was
to explore the quality, timing, and outcomes of bleed-
ing events in patients treated on idelalisib registrational
trials. Overall, we found a similar low grade of severity
of bleeding events related to the use of anticoagulant/
antiplatelet agents in patients with iNHL and CLL, as
well as in patients treated with idelalisib (monotherapy
or in combination with the monoclonal antibody rituxi-
mab) when compared with rituximab alone.
Cardiovascular comorbidities were prevalent in
patients participating in the idelalisib trials (85% and
41% in the CLL and iNHL cohorts, respectively), which
appeared to be similar to that seen in the real-world
setting for these types of patients [23], resulting in a
considerable rate of anticoagulant/antiplatelet use
amongst trial participants. The majority of bleeding
events were grade 2, with no reports of central ner-
vous system hemorrhage. These events occurred pre-
dominantly during the first 3months on trial, with
similar frequency in patients treated with idelali-
sibþ rituximab, placeboþ rituximab, and idelalisib
monotherapy, irrespective of concomitant antiplatelet/
anticoagulant therapy including warfarin, suggesting
the possibility that the bleeding was more a result
from baseline thrombocytopenia rather than drug
exposure. Warfarin use was not an exclusion criterion
to participate in any of the idelalisib clinical trials.
Data regarding dose intensity and therapeutic ranges
of the anticoagulant/antiplatelet agents at the time of
the bleeding events were not collected; thus, any con-
tribution of supratherapeutic levels at the time of the
events to the severity of the events is not known.
Concomitant use of anticoagulant/antiplatelet drugs
in these studies was comparable to that reported for
studies with ibrutinib. An integrated analysis of inci-
dence and risk factors for major hemorrhage in 15 ibru-
tinib clinical studies revealed common anticoagulant/
antiplatelet use in approximately 50% of patients [24].
In the phase3 RESONATE trial of ibrutinib in patients
with previously-treated CLL/SLL (NCT01578707), of four
ibrutinib-treated patients who experienced major hem-
orrhage, two used concomitant anticoagulant/antipla-
telet medications [25]. Anticoagulant/antiplatelet use in
the current analysis was also comparable to clinical
practice use in similarly age-matched patients with CLL
and iNHL in a prescription and medical claims database
analysis in which an estimated 15% of patients with
CLL and 14% with iNHL were taking anticoagulant/anti-
platelet medications (excluding aspirin) in 2014 [11].
Since our study was not randomized based on use of
anticoagulant/antiplatelet agents, there is a higher inci-
dence of concomitant anticoagulant/antiplatelet use in
the idelalisibþ rituximab cohort compared with the
placeboþ rituximab cohort, without apparent clinical
consequence. The overall incidence of bleeding events
was similar in these two groups. The exposure-adjusted
incidence rate of bleeding events was actually lower in
the idelalisib group than in the rituximab-treated
group and lowest in the iNHL patients treated with ide-
lalisib monotherapy. Interestingly, the iNHL cohort had
a longer median time to bleeding event (6months
compared to 1month). Moreover, the frequency of
events did not increase with idelalisib exposure despite
differences in the disease biology and clinical behavior
of patients with a CLL vs iNHL diagnosis. This may be a
consequence of improvement of the thrombocyto-
penia in the idelalisib treatment arms, particularly in
patients with severe baseline thrombocytopenia.
There are limitations to this study, and these data
should be interpreted with caution. These clinical trials
were not designed to assess bleeding events with ide-
lalisib. In particular, hemorrhage was not identified as
a toxicity of special interest, so under-reporting of
bleeding events by the investigator may have
occurred. Due to the post hoc nature of this analysis
and the small patient numbers, substantive statistical
comparisons between treatment groups were not feas-
ible. Additionally, the follow-up time was relatively
short, and longer studies may be needed to elucidate
whether prolonged idelalisib exposure affects the out-
comes. Despite these limitations, the analyses were
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warranted, as there is a paucity of data on bleeding
events with the use of PI3Kd inhibitors. A major limita-
tion to the present study is the known toxicity profile
of idelalisib [19,20], which may have reduced overall
dose intensity and adherence based on the need to
withhold the drug to permit toxicity resolution.
However, the exposure-adjusted bleeding rates would
normalize for this potential bias. On the other hand, a
drug-related toxicity such as colitis could further
increase an inherent risk to the development of
gastrointestinal bleeding.
Importantly, the incidence of bleeding events may also
have been confounded by patients’ baseline thrombocyto-
penic status. Twice as many patients with grade 3
thrombocytopenia at baseline experienced bleeding
events compared to those that did not have severe
thrombocytopenia. We found that platelet counts
remained stable or improved while on treatment with ide-
lalisib, with more pronounced improvements in patients
with baseline thrombocytopenia <100K/lL. Our findings
suggest that idelalisib use did not increase bleeding events
even in the presence of antiplatelet/anticoagulant use;
rather, bleeding events were associated with underlying
disease states (i.e. thrombocytopenia from bone marrow
infiltration or myelosuppression from recent cytotoxic
chemotherapy) or the concomitant use of warfarin.
To conclude, this study shows no difference in the
frequency of bleeding events related to the use of
anticoagulant and/or antiplatelet agents in patients
with CLL and iNHL treated with idelalisib. Although
idelalisib is well known to cause other serious or even
fatal toxicities (colitis, pneumonitis, transaminitis, and
infections), our data show no increase in bleeding
events in patients with relapsed/refractory CLL or iNHL
treated with idelalisib. The modest rate of bleeding
events in patients treated with idelalisib (± rituximab)
was similar when compared to rituximab monotherapy
use. Although the data presented do not change the
known risk-benefit profile for idelalisib use, it may be
informative when considering next-line therapy for
patients with relapsed/refractory CLL or iNHL at high
risk for major bleeding events.
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